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INTRODUCTION
Lysosomal storage disorders (LSDs) comprise a group of rare inherited chronic diseases characterized by the deficiency of specific enzymes at the lysosomal compartment, and the accumulation within these organelles of the macromolecular compounds catabolized by those enzymes. 1 Although individual LSDs have incidences of less than 1:100,000, as a group the incidence is calculated to be 1 in 7,700. 2 Nowadays, pharmacological treatment is only available for few of the about 50 known
LSDs. In most cases such treatment is based on enzyme replacement therapy (ERT), in which purified recombinant enzyme is infused into the patient. Generally, the efficacy of many ERTs is limited due to the fact that exogenously provided enzymes do not have effect on all clinical aspects of the disease, partly due to the irreversibility of some of them, but also due to enzyme formulations failure to reach all major target organs in therapeutically efficacious doses. 3 Thus, delivery of therapeutic biomacromolecules to specific cellular types and subcellular compartments is a key objective in drug delivery.
In particular, lysosomal targeting and delivery in various specific tissues has become of great interest due to the clinical relevance of enzymes and proteins acting within the lysosome.
Nanoparticle-based drug delivery has been used to improve the activity and delivery of therapeutic macromolecules, like proteins and DNA, providing longer blood circulation times and protecting sensitive biomacromolecules from protease degradation and immune system reactions. 4 Within the context of protein delivery systems, stimulitriggered release is an appealing and promising approach, especially with the use of physiological stimuli like the pH drop within endo-lysosomal compartments. 5, 6 In addition, addressing clinically relevant end points by targeted delivery has emerged as an approach to maximize the efficiency of a therapeutic macromolecule by strictly 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5 localizing its pharmacological activity through controlled biodistribution. 7, 8 Drug delivery to the nucleus or cytoplasm has been extensively explored, 9 however, lysosomal delivery has only lately turned into the focus of attention. 5, [10] [11] [12] [13] [14] [15] [16] [17] The current ERT therapy relies in the natural cellular transit of lysosomal enzymes.
As a rule, lysosomal enzymes are produced in the endoplasmic reticulum, glycosylated at the Golgi apparatus, where the mannose-6-phosphate (M6P) is added, and then secreted to the extracellular space. Thereafter, the enzyme is available for the cells to be internalized through M6P receptors and localized in the lysosomes. This is the mechanism that allows the ERT 18 and the reason why enzymes administered by ERT have been genetically modified to exhibit an increased glycosylation, allowing better interactions through cell-surface receptors that recognize the carbohydrate moieties.
However, alternative enzyme targeting approaches might be necessary to enhance not only the lysosomal destiny of the enzyme but also enzyme accumulation in specific cell types.
α-galactosidase A (GLA) is the lysosomal enzyme responsible for the degradation of globotriaosylceramide (Gb3) and other neutral glycosphyngolipids. Its deficiency causes the Fabry disease, resulting in the accumulation of Gb3 in the lysosomes of various cells and tissues, mainly at the vascular endothelium. [19] [20] [21] Therefore, endothelial cells (EC) represent a main target for therapeutical intervention in Fabry disease. Target determinants like E-selectin, VCAM-1, ICAM-1 and integrins like α v β 3 and α v β 5 with expression restricted to EC and upregulated during inflammation or angiogenesis, may help to achieve specific and safe delivery of drugs into EC subsets involved in diseases, thereby improving pharmacological efficacy. 22, 23 Peptide ligands containing the arginine-glycine-aspartic acid (RGD) sequence display a strong binding affinity and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6 selectivity to integrins, particularly to integrin α v β 3 , and have been conjugated to several conventional therapeutic agents for EC targeting and endosomal delivery. [24] [25] [26] [27] Previously, we have described for the first time the development of a pH-responsive nanocarrier for lysosomal delivery of proteins, based on the ionotropic gelation of complexes between trimethyl chitosan (TMC) and the lysosomal enzyme GLA, with triphosphate ions. 5 With a good protein loading efficiency (around 65%), these polyelectrolyte complexes (PECs) have appropriate physicochemical properties to remain stable at physiological temperature and pH (around 7.5), and dissociate and release the protein content at endosomal/lysosomal values (pH 4.5 to 5.5). We proved that these PECs were efficiently internalized by human cells and mostly accumulated in lysosomal compartments, demonstrating their enormous potential as advanced protein delivery systems for treatment of lysosomal storage diseases. 5 Following these results, in this work we evaluated the intracellular activity of the PECs, and the possibility to enhance the efficacy of the TMC-based PECs to deliver GLA into the lysosomes of EC by introducing RGD motifs (PEC-RGD). We therefore prepared PEC and PEC-RGD and assessed their physicochemical properties, cytotoxicity and hemocompatibility, as well as cellular uptake by ECs. We further investigated the intracellular activity in primary cultures of mouse aortic endothelial cells of GLA deficient mice (MAEC KO cells). In view of optimizing the PEC storage conditions, we also explored the freeze-drying process and the effect on the GLA activity.
EXPERIMENTAL SECTION

Synthesis of N-trimethyl chitosan
Trimethyl chitosan (TMC) was prepared from chitosan middle-viscous (CS, Fluka) with a degree of deacetylation of ∼87%. 5 via a two-step procedure, 28 as reported 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   7 previously. 5 Briefly, a mixture of 2 g of sieved chitosan, 4.8 g of sodium iodide (NaI), 11 mL of a 15% aqueous sodium hydroxide (NaOH) solution and 11.5 mL of methyl iodide (CH 3 I) in 80 mL of 1-methyl-2-pyrrolidinone was stirred at 60 °C for 1 h.
Special care was taken to keep the methyl iodide in the reaction mixture by using a Liebig condenser. The product was precipitated using ethanol and thereafter isolated by centrifugation. The N-trimethyl chitosan iodide obtained after this first step was washed twice with ether on a glass filter to remove the ethanol. It was then dissolved in 80 mL of 1-methyl-2-pyrrolidinone and heated to 60ºC, thus removing most of the absorbed ether. In a second step, further 4.8 g of NaI, 11 mL of 15% NaOH solution and 7 mL of CH 3 I were added (second addition) with rapid stirring and the mixture was kept at 60 °C for 30 min. Additional 2 mL of CH 3 I and 0.6 g of NaOH pellets were added and the stirring was continued for 1 h. The product, precipitated with ethanol as described above, was dissolved in 40 mL of a 10% sodium chloride (NaCl) aqueous solution to exchange the iodide. The polymer was precipitated with ethanol, isolated by centrifugation and thoroughly washed with ethanol and ether. In vacuum drying yielded a white, water-soluble product. Finally, it was dissolved in water and freeze-dried (freeze dryer ALPHA 1-4 LD, Christ). The product was partially quaternized chitosan with ca. 50% of quaternary amines and around 28% degree of primary amines (free amines), as determined by 1H NMR. We also observed 22 and 31% of O-methylation for C-3 and C-6, respectively. 29 The molecular weight of the TMC was estimated to be 202000 g mol -1 with a polydispersity of 2.6, via gel permeation chromatography (GPC), using Ultrahydrogel 250 and 500 columns and a Waters 24/4 IR detector, in acetate buffer 0.5 M, pH 3. Dextran standards were employed for calibration. The product had a pKa value of 6.1 and was fully soluble in both water and HEPES buffer at pH 7.4 to 7.5. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 8 TMC was conjugated to the fluorescent dye Atto 647N NHS ester (Fluka). Atto 647N
Fluorescently labeled TMC (TMC-Atto)
NHS was first dissolved in dimethyl sulfoxide (DMSO) and then diluted with buffer HEPES 10 mM pH 7.4. This solution was added to a TMC solution (in HEPES 10 mM pH 7.4) in an approximate molar ratio of 3:1, and left to react for 1 h at room temperature under magnetic stirring. Atto 647N-conjugated TMC was separated from the free dye using Zeba desalt spin columns (Thermo Scientific). In order to increase the amount of conjugated Atto 647N, a second step was performed and the product was reacted with freshly prepared Atto 647N NHS solution for another hour and, afterwards, separated with Zeba desalt spin columns. The dye-modified TMC (TMC-Atto) solution was freeze-dried (freeze dryer VirTis Freezemobile 25L, SP Scientific, UK). The amount of dye was estimated to be 0.32 moles dye per mol TMC, via UV-visible spectrometry (NanoDrop Spectrophotometer ND-1000, Thermo Scientific). TMC-Atto was stored at -20 ºC.
RGD-peptide conjugation to TMC (TMC-RGD)
A RGD cyclic peptide c(RGDfK) derivatized with N-succinimidyl S-acetylthioacetate (SATA) through the ε-amine of the lysine was obtained following procedures previously described. 11, 30, 31 Briefly, the linear peptide was synthesized using standard SPPS on a 2-chlorotrityl chloride resin. After cleavage with Acetic Acid/TFE/DCM All PECs were characterized and used as obtained, without further purification or separation steps. When necessary, they were stored at 4 ºC.
Freeze-drying of PECs
Prior to freeze drying (FD), the eutectic point of PEC suspensions was determined by means of resistivity measurements, using an Autolab PGSTAT 12 potentiostat (EcoChemie, NL). In all samples tested, the eutectic point was within the temperature range from -23.3 ºC to -24.5 ºC. Therefore, freezing at -40 ºC (the standard freezing temperature of the employed freeze-dryer) seemed a reasonable safety limit (without relevant loss of sublimation motive strength), even if lower temperatures were also tested when freezing in liquid nitrogen.
FD vials (4 mL) were filled with 1 mL PECs suspension. A LyoMega-30 freeze-dryer (Telstar, Terrassa, Spain) equipped with product temperature probes was used.
Moreover, 40 µL of a 5% mannitol solution in HEPES 10 mM, pH 7.4 were added in half of the samples in order to get isoosmotic solutions. The conditions for the different freeze-drying cycles tested are detailed in Table 1 . All freeze-dried PECs were stored at 4 ºC, and before characterization 1 mL of ultrapure water was injected inside the vials for resuspension. Samples were thereafter identified with the freeze-drying cycle employed (FD1, FD2 or FD3), and an M in case mannitol was introduced. Sublimation T (ºC) +20 +20 +20
Vacuum limit (µmHg) 300 300 300
Total duration (h) 30 24 18
Dynamic light scattering characterization
Size and size distribution of PECs was characterized by dynamic light scattering 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 with FBS, antibiotics and L-glutamine. Both cell lines were kept in a 37 ºC humidified atmosphere with 5% CO 2 . Media, sera and antibiotics were purchased from Invitrogen.
Cell line cultures
Cytotoxicity and hemocompatibility of PECs
Biocompatibility of freshly prepared PECs was evaluated as previously described. 34, 35 Briefly, cell cytotoxicity was tested using 3 
Cell internalization
To study the integrin mediated internalization of freshly prepared PECs, HMEC-1 cells were incubated with Atto 647-labeled PECs (12.5 µg mL -1 ) resuspended into MCDB 131 without FBS for 10 or 20 min at 37 ºC. Cells were subsequently washed twice with Dulbecco's phosphate buffered saline (DPBS) solution and subjected to 
Specific enzymatic activity
GLA enzymatic activity was assayed fluorometrically as described by Desnick et al. 36 with the modifications of Mayes et al. 37 Basically, it was assayed by using 4- confirming that the integrity of MAEC cells was not affected by the complex incubation. Since GLA activity reduces those Gb3 deposits, the percentage of Gb3 loss (% Gb3 loss = 100 -% Gb3-NBD signal) was used to plot the results. When needed, IC50 values were calculated using GraphPad Prism 5 software.
NBD-Gb3 assays in endothelial primary cultures of Fabry mice
Animal experimentation
C57Bl6 wild type animals and Gla tm1Kul GLA deficient mice 39 were used as source of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16
RESULTS
Preparation and characterization of RGD-conjugated and fluorescently labeled PECs
The polyelectrolyte complexes (PECs) between GLA and TMC were prepared by ionotropic gelation with penta-sodium triphosphate, as previously reported, 5 and characterized by DLS. We obtained particles with diameters in the range of 170 to 215 nm at room temperature, and ξ-potential values around 19 mV (Table 2) .
To obtain RGD-conjugated-PECs (PEC-RGD), the mass ratio TMC:TMC-RGD was varied between 100:0 and 50:50, and the PECs were prepared and characterized by DLS. We found that the incorporation of TMC-RGD lead to a slight decrease of PECs zeta potential value (19 mV for PEC and 17 mV for PEC-RGD) with no significant variation of the average diameter when up to 50% TMC was replaced by TMC-RGD (Table 2 ). In view of the small change observed for the system, we performed additional studies with the PEC-RGD obtained using a TMC:TMC-RGD mass ratio of 50:50.
In a similar manner, TMC was replaced in part by TMC-Atto to obtain fluorescently labeled PECs (PEC-Atto), or by TMC-RGD and TMC-Atto, to obtain fluorescently labeled RGD-conjugated PECs (PEC-Atto-RGD) (see Experimental section). As shown in Table 2 , the introduction of the fluorochrome did not significantly alter the PECs size. The ξ-potential of both PEC-Atto and PEC-Atto-RGD was around 16 mV, slightly lower than that for PEC. PEC labeled Atto 647N have been characterized by singlemolecule fluorescence in a previous report, 5 revealing that they were homogeneous in size and possessed good colloidal stability in water/HEPES and serum free cell culture medium. 
Physico-chemical characterization of freeze-dried PEC
PEC suspensions were freeze-dried following 3 different freezing protocols (see
Experimental section).
PECs were characterized within 24 h after preparation, whereas freeze-dried PECs were characterized immediately after resuspension.
Remarkable differences were observed between different FD cycles (see Table 3 ).
Regarding particle size, a notable reduction in the average diameter was observed when using FD2 cycle, resulting in a compaction of the particles, and the addition of mannitol did not cause any particle size increase. As displayed in the examples of Figure 1 , the size distribution for PEC-FD2 and PEC-FD2-M was unimodal. Instead, when freezedrying following FD1 and FD3 cycles, a slight diameter increase was observed, being almost twofold when mannitol was added. On the other hand, higher PDI values were obtained for all particles after freeze-drying, even if these were lower than 0.3 for PEC-FD1, PEC-FD2 and PEC-FD2-M, which are still acceptable PDI values. Besides, minor ξ-potential decrease was observed after freeze-drying by cycles FD1 and FD2, whereas an important drop off was achieved after freeze-drying by cycle FD3. However, in general terms, lower ξ-potential values are obtained in formulations containing mannitol. Therefore, FD cycle 2 resulted in good preservation of the structure after resuspension. 
Cytotoxicity and hemocompatibility
It has been proposed that strong interaction of cationic nanoparticles with the cell membrane may cause damage by membrane disruption, leading to cell death. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20
To test the hemocompatibility of freshly prepared PEC and PEC-RGD, the percentage of hemolysis of mouse RBC was assessed for different PEC or PEC-RGD concentrations up to 2.7 µg mL -1 . Hemolysis for both PEC and PEC-RGD was always
lower than 1% for the tested concentrations (Figure 3 ). These results indicate that both PEC and PEC-RGD cytotoxicity is very low and they do not induce hemolysis in concentrations below 5.5 µg mL -1 . 
Cell internalization
21
We have demonstrated in a previous work that the GLA loaded PEC are easily taken up by endothelial cells and localized in the lysosomal compartments, when incubated in vitro for 2 h. 5 In the present work, we aimed at comparing the uptake efficiency of PEC 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 given number of cells counted and b) mean fluorescence intensity (MFI) of Atto 647N
in the cells normalized to the maximum fluorescence intensity.
Specific enzymatic activity and activity in primary cultures: Gb3 loss in endothelial primary cultures of Fabry mice
Since GLA activity reduces Gb3 deposits within the lysosomes, the efficacy of different PECs to diminish the intracellular Gb3 deposits was assessed in cell cultures and compared to the activity of free GLA. The percentage of Gb3 loss of primary cultures of mouse aortic endothelial cells (MAEC) of GLA deficient mice was evaluated after simultaneous incubation with fluorescently labeled Gb3 (NBD-Gb3) and GLA, PEC or PEC-RGD in different concentrations. Degradation of NBD-Gb3 by GLA occurs exclusively inside the late endosomes/lysosomes, where the pH conditions are the most favorable for the enzyme activity. Outside these organelles, the pH is higher, and not optimal for the GLA enzymatic activity. Even when GLA and NBD-Gb3 are incubated simultaneously with the cells, the reaction only takes place when both components are internalized in the lysosomes.
Before moving into the cellular activity assays, the specific enzymatic activity of free GLA, and freshly prepared PEC and PEC-RGD was first assessed following the degradation of 4-MUG fluorometrically, in the conditions described in the Experimental section (section 2.10). The specific activity of the GLA is in some extent altered by the encapsulation process, as detailed in Table 4 . A decrease in activity after encapsulation has previously been observed for GLA loaded TMC-based PEC 5 and it is probably related to the more difficult accessibility to the substrate. Dissociation of the PECs and accessibility of the enzyme to the substrate is expected to be easier in the lysosome, with presence of many degrading enzymes, than in the test tube. Figure 5 displays the Gb3 loss, obtained from the reduction in fluorescence due to the degradation of NBD-Gb3, plotted against the concentration of activity of GLA of the free GLA, freshly prepared PEC or PEG-RGD suspensions. The GLA concentration is represented in activity units (U mL -1 ) due to the variations in specific activity for the different samples tested. The curves show higher efficacy for both PEC and PEC-RGD when compared to free GLA, as there is a 50% loss of Gb3 (IC50) already at 7.6 ± 0.9 and 5.5 ± 1.5 mU mL -1 activity for PEC and PEC-RGD, respectively, while for the free GLA this occurs at an activity of 50.3 ± 8.1 mU mL -1 . These results suggest that GLA is better internalized by MAEC when loaded in the PECs, increasing significantly the efficacy (IC50 values for the Gb3 loss is 7.6 ± 0.9 mU mL -1 for PEC while naked GLA requires 50.3 ± 8.1 mU mL -1 ). In addition, the slight decrease in IC50 for the RGD decorated PEC (IC50 values of 5.5 ± 1.5 mU mL -1 ) may be associated with the higher internalization degree observed already in HMEC-1 when compared to the bare PECs. The enzymatic activity of the freeze-dried PEC was tested immediately after resuspension in MilliQ water, and compared with the specific activity of the stock PEC suspension. Results in Table 5 show that the freeze-drying process not only does not affect the enzymatic activity of the encapsulated GLA, but also helps to preserve its activity, since all FD-PECs show higher enzymatic activity than the fresh PECs tested after 4 days of preparation. This result is very clearly evidenced in the percentage of activity recovered displayed in Table 5 with respect to fresh GLA, and with respect to fresh PECs of the same batch. When PECs tested 4 days after synthesis retain only 20 % of the specific activity of the free fresh GLA, when PECs are FD and resuspended, this percentage raises up to almost 50% in the best case. Besides, the presence of mannitol in the freeze-drying medium does not have a direct effect on the enzymatic activity in the test tube. Finally, although all freeze-dried PECs display good enzymatic activity after resuspension, the maximum activity is obtained after the freeze drying cycle 2 (FD2). Accordingly, the intracellular activity of the PEC-FD2 was assessed and compared with that of the freshly prepared PECs. Figure 6 displays the Gb3 loss plotted against the concentration of activity of GLA for PEC, PEC-FD2 and PEC-FD2-M suspensions. Both PEC-FD2 and PEC-FD2-M display higher efficacy than PEC, with a 50% loss of Gb3 (IC50) at 1.5 ± 0.2 and 1.3 ± 0.2 mU mL -1 activity for PEC-FD2 and PEC-FD2-M, respectively, and at 5.9 ± 0.5 mU mL -1 for PEC, probably due to the stabilization of the PEC complex after freeze-drying procedure. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   27 crosslinker. 5 The ionic nature of the PECs has the advantage of simple preparation procedures, due to the self-assembling nature of the system, which is of great importance when the cargo is a biomacromolecule, sensitive to harsh synthesis conditions like high temperatures, solvents or extreme pH. 42 In addition, it permits tailoring of the nanoparticle properties by modifying only one of the PECs components, the TMC in this case. Using this strategy, we have developed PECs capable to selfassemble at neutral pH by simply mixing components and stirring, and disassemble at endo-lysosomal acidic pH, where the GLA is active. 43 The PECs have average D between 170 and 250 nm and very low PDI (0.1-0.2) measured by DLS, and positive ξ-potential in the range of 16-19 mV at pH 7.4 ( Table 2 ), suggesting that the nanoparticles surface expose mainly TMC than GLA, as the protein is negatively charged at neutral pH.
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It has been proposed that the strong interaction of cationic nanoparticles with the negatively charged cell membrane may cause membrane disruption, leading to cell death, 40 but it is also evidence that the toxicity of cationic nanoparticles depends on cellspecific uptake mechanisms and pathways. 45 Following safety concerns for future in vivo applications, we investigated the potential toxicity of the PECs on HeLa, a routinely used cell line for cytotoxicity evaluation, and HMEC-1 cells, as vascular endothelial cells represent the main target for therapeutics in Fabry disease. [19] [20] [21] For PEC concentrations up to 5.5 µg mL -1 cell viability is not significantly affected, maintained around 80% (Figure 2) . Besides, hemolysis of the PECs suspensions was always lower than 1% when tested against mouse RBC (Figure 3) , clearly below the 5% value considered as the toxicity threshold. These results are in agreement with other reports on TMC based nanovectors with low toxicity 46 and also show a correlation of the cytotoxicity with other structural parameters besides surface charge, like size of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 28 nanoparticles, molecular weight of chitosan and acetylation degree. 47 Moreover, the lowered buffering capacity of chitosan after methylation 5 prevents endo-lysosomal disruption and scape, 48 which in combination with the dissociation capacity of the PECs at low pH 5 and the eventual TMC degradation by lysosomal enzymes, 49 may preserve lysosomal function after PECs internalization.
In previous studies we demonstrated that the PECs were efficiently internalized by HMEC-1 cells in vitro, after 2 h incubation, with endosomal/lysosomal destination confirmed by multicolor fluorescence microscopy. 5 This nonspecific cell uptake most likely takes place by adsorptive endocytosis. 50, 51 Here, we explored the introduction of peptides ligands that include the RGD motif in the PECs structure, to target integrins like α v β 3 , expressed in endothelial cells and upregulated during inflammation or angiogenesis and also in Fabry patients. [22] [23] [24] [25] [26] [27] 52 Indeed, the addition of the RGD motif has long been seen as a way to enhance the cellular internalization of otherwise slowly internalizing nanosystems 26 and viruses. 53 In our hands, the same cyclic RGD peptide has been introduced previously to nanoliposomes and polyurethane-polyurea nanocapsules enhancing the internalization and the lysosomal localization of the nanosystem. 11, 30 Conjugation of c(RGDfk) to TMC is a simple procedure, and allows obtaining RGD-conjugated-PECs (PEC-RGD), without significant alterations of the particle average diameter and a slight decrease in ξ-potential value (Table 2) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 also maintaining average D and with a minor decrease in ξ-potential (Table 1) . When comparing the internalization of PEC and PEC-RGD by HMEC-1 after incubation for short times, i.e. 10 and 20 min, an increase in the number of positive cells was observed for both PEC and PEC-RGD over time (Figure 4) . However, statistically significant difference in the amount of positive cells between PEC and PEC-RGD uptake was mainly observed at 10 min incubation time. It is important to take into account that, due to the preparation method, it is not possible to control the location and orientation of the RGD motif within the PEC. The addition of TMC and TMC-RGD solutions to the GLA + TPP solution is done in subsequent steps, in order for the first complexes to be formed with the TMC, and then complete the particle formation with the TMC-RGD. We expect that the amount of RGD be higher on the outer layers of the PEC than on the core; however, we have no evidence to support this hypothesis. Still, even when HMEC-1 internalization occurs fast and in great extent for both PEC and PEC-RGD, the enhanced uptake of RGD decorated PEC at short incubation times is evidenced (Figure 4) , suggesting a quick and efficient receptor-mediated uptake, or at least a combination of both nonspecific and receptor-mediated endocytosis.
Preservation of enzymatic activity of GLA after encapsulation in the PECs is essential. A first, test following the degradation of 4-MUG fluorometrically revealed that GLA in PECs is active, but shows a decrease in activity after encapsulation (Table   4 ). This might be related to a hampered accessibility of the substrate because of a partial association of the enzyme and TMC persisting at acidic pH. However, it is expected that in the lysosomal environment, pH-triggered release will be accompanied by the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 As shown, results were promising, as both PEC and PEC-RGD display higher activity in MAEC KO cells than free GLA ( Figure 5 ) with significantly lower IC50 (50.3 mU mL -1 for GLA and 7.6 and 5.5 mU mL -1 for PEC and PEC-RGD, respectively). Since the GLA requires the low pH at the lysosomes to be active, no metabolization of the NBD-Gb3 can occur outside the lysosome by the enzyme. 43 A first observation is that, as already suggested by the cell internalization studies by FACS, both PEC and PEC-RGD destination is the lysosomes. Notably, an important increase in intracellular activity is happening when GLA is encapsulated in PECs respect to the free GLA, even when certain loss of specific activity of GLA after encapsulation is happening.
Consequently, less activity units of GLA are necessary to degrade Gb3 when the enzyme is encapsulated. It has been recently reported the increase of GLA activity when associated to liposomes, 11 which has been related to the immobilization of the enzyme onto the lipid bilayer. A similar effect may be happening when GLA is interacting with TMC after PECs are dissociated inside the endo/lysosomal compartments, and partial association with TMC may still take place. Moreover, an increased efficiency due to the RGD ligand is detected, probably due to a higher internalization degree, or even to a more favorable uptake mechanism. It is well documented that nonspecific cell uptake of nanocarriers occurs mainly by endocytic process, 56 and integrin-mediated internalization occurs when the carrier interacts with the cell surface receptors and are taken up into the target cells via receptor-mediated endocytosis. In both cases, the resulting endocytic vesicles fuse to form early endosomes and then mature into late endosomes which ultimately become part of the lysosomes. 22 The occurrence of the uptake via the two different mechanisms is here suggested by the enhanced internalization observed in vitro for PEC-RGD than for PEC. This opens the possibility of an alternative glycosylation independent targeting 55, 57 for ERT, and might facilitate 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 31 the use of non-glycosylated or partially glycosylated enzymes for treatment of LSD via ERT. Thus, GLA encapsulation will also endure a protection effect against GLA opsonization in the blood stream as previously demonstrated for other systems. 58, 59 Increased cellular levels of GLA or its activity in plasma have recently been reported on systems where GLA is also stabilized by other means, such as crosslinking and PEGylation, giving a prolonged circulatory half-life, 58 or by the use of chaperones like Migalastat HCl. 59 Moreover, the increased advantage in the intracellular efficacy of the GLA when associated to the TMC in the PECs, particularly when decorated with RGD targeting moieties, would likely be evidenced when testing them in in vivo Fabry murine experimental models.
Finally, we have demonstrated that the PECs can be freeze-dried (FD) under controlled conditions to be preserved and administrated thereafter. We explored several FD cycles and the introduction of mannitol (PEC-FD-M), commonly used as a cryoprotector but also to achieve isosmotic solutions, to see its effect on the structure and properties of PEC-FD. Evaluating the physicochemical properties of the PECs after resuspension and the GLA enzymatic activity after the whole cycle allowed determining the optimal FD conditions (FD2), i.e. fasting freezing at -40 º C. Using this cycle, the size and ξ-potential of the PECs after resuspension was not altered (Table 3 and Figure   1 ) and the specific enzymatic activity of the GLA was preserved (Table 5) , for both PECs with and without mannitol. The presence of mannitol did not introduce any change in physicochemical of the PECs or the biochemical properties of the loaded GLA. PEC-FD2 (as well as PEC-FD2-M) showed higher specific enzymatic activity than fresh PECs, probably due to the fact that the tests were performed 4 days after preparation, and while fresh PECs could lose part of the GLA structure and activity, FD-PEC preserved it. 60 Not only was a higher specific enzymatic activity observed for Figure 6 ). Subsequently, when comparing PEC-FD2 with the free GLA in suspension, the increase in efficacy is very high, with IC50 values from 50.3 to 1.5 mU mL -1 . The FD process is a crucial step to preserve the PECs stable and active, and it could also serve as a way to slightly concentrate the sample when needed.
CONCLUSIONS
We have developed a versatile protein lysosomal delivery PEC based on the negatively charged lysosomal enzyme GLA, deficient in the LSD Fabry disease, and TMC, ionically crosslinked with TPP. Given its simple preparation strategy, it allows functionalization via conjugation of TMC with different moieties, like fluorophores and ligands, and also changing the cargo protein to tackle other LSDs. We evaluated the intracellular activity of the GLA loaded PECs, and the possibility of enhancing their efficacy as lysosomal delivery vectors in endothelial cells by introducing the RGD motif in the nanocarriers (PEC-RGD). We successfully prepared PEC and PEC-RGD with good physicochemical properties, low cytotoxicity and good hemocompatibility.
PECs were efficiently taken up by endothelial cells in vitro, and the internalization was significantly higher for PEC-RGD than for PECs at short incubation times. Even more,
we demonstrated an enhanced efficacy of PEC and PEC-RGD as compared to free GLA when evaluating the intracellular activity in primary cultures of GLA deficient mice.
Relevantly, we optimized a FD protocol that allowed maintaining the physicochemical properties of the PECs while improving the biochemical ones, preserving the specific enzymatic activity of GLA and enhancing the efficacy in vitro in MAEC KO cells. The FD process is essential to preserve the PECs stable and active, and also could serve as a 
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